Hydrocortisone acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Hydrocortisone acetate
• 英文别名: Hydrocortisonacetat；11,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl acetate；[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl] acetate
• 化学式: C₂₃H₃₂O₆
• 分子量: 404.503
• InChiKey: ALEXXDVDDISNDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [2-(9-Bromo-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] acetate 在 次磷酸 、 potassium carbonate 、 1,1'-偶氮(氰基环己烷) 作用下， 以 2-甲基四氢呋喃 、 水 为溶剂， 以85.3%的产率得到Hydrocortisone acetate
  参考文献：
  名称：

  9-卤代甾体化合物的脱卤方法及应用

  摘要：

  本发明提供了一种9‑卤代甾体化合物的脱卤方法及应用，涉及化学合成技术领域。9‑卤代甾体化合物的脱卤方法，包括如下步骤：化合物I与氢供体和偶氮类自由基引发剂反应，得到9‑卤代甾体化合物的9位脱卤产物化合物II。本发明提供的9‑卤代甾体化合物的脱卤方法，氢供体采用次磷酸及次磷酸盐、甲酸及甲酸盐、有机硅氢化物、肼类化合物或环己烯中的一种或几种的组合，引发剂采用偶氮类自由基引发剂，反应中未使用铬、二价铬盐、三价铬盐或氢化三丁基锡等毒性较大，对环境造成严重污染的试剂，绿色环保，合成工艺简便易行，提高了生产适用性。

  公开号：

  CN112142813A

文献信息

• CORTICOSTEROID CONJUGATES AND USES THEREOF
  申请人：Teicher Martin H.

  公开号：US20100056488A1

  公开（公告）日：2010-03-04

  The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate.
• Oligomer-Corticosteroid Conjugates
  申请人：Zhang Wen

  公开号：US20100286107A1

  公开（公告）日：2010-11-11

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.
• OLIGOMER-CORTICOSTEROID CONJUGATES
  申请人：NAKTAR THERAPEUTICS

  公开号：US20140309398A1

  公开（公告）日：2014-10-16

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits different properties compared to the properties of the corticosteroid not attached to the water-soluble oligomer.
• US8796248B2
  申请人：——

  公开号：US8796248B2

  公开（公告）日：2014-08-05
• [EN] OLIGOMER-CORTICOSTEROID CONJUGATES<br/>[FR] CONJUGUÉS D'OLIGOMÈRES ET CORTICOSTÉROÏDES
  申请人：NEKTAR THERAPEUTICS AL CORP

  公开号：WO2009045539A2

  公开（公告）日：2009-04-09

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.

表征谱图